Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90

Molecular and Cellular Biochemistry

Volumn 348, Issue 1-2, 2011, Pages 165-171

  Meng, Qingwei ^a   Chen, Xuesong ^a   Sun, Lichun ^a   Zhao, Changhong ^a   Sui, Guangjie ^a   Cai, Li ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Acetylation; Carbamazepine; Degradation; Heat shock protein 90 (Hsp90); Her 2; Histone deacetylase 6 (HDAC6)

Indexed keywords

ALPHA TUBULIN; CARBAMAZEPINE; CHAPERONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 6; MESSENGER RNA; PROTEASOME; TRASTUZUMAB;

ACETYLATION; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION;

ACETYLATION; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOQUINONES; BREAST NEOPLASMS; CARBAMAZEPINE; CELL LINE, TUMOR; CELL PROLIFERATION; CYSTEINE PROTEINASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LEUPEPTINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; RECEPTOR, ERBB-2; RNA, MESSENGER; TIME FACTORS; TUBULIN;

EID: 78651304171     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-010-0651-y     Document Type: Article

References (30)

1. MA Cobleigh CL Vogel D Tripathy NJ Robert S Scholl L Fehrenbacher JM Wolter V Paton S Shak G Lieberman DJ Slamon 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639 2648 1:CAS:528:DyaK1MXmtlWrurk%3D 10561337
2. J Andersson B Linderholm G Greim B Lindh H Lindman J Tennvall L Tennvall-Nittby D Pettersson-Sköld A Sverrisdottir M Söderberg S Klaar J Bergh 2002 A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin) on a named patient basis in Sweden Acta Oncol 41 276 281 10.1080/02841860260088827 12195747 (Pubitemid 34833052)
3. RH Engel VG Kaklamani 2007 HER2-positive breast cancer: current and future treatment strategies Drugs 67 1329 1341 1:CAS:528:DC%2BD2sXptVyku7s%3D 10.2165/00003495-200767090-00006 17547474 (Pubitemid 46879097)
4. DJ Slamon W Godolphin LA Jones JA Holt SG Wong DE Keith WJ Levin SG Stuart J Udove A Ullrich 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707 712 1:STN:280:DyaL1M3kt1Wntg%3D%3D 10.1126/science.2470152 2470152
5. D Pils A Pinter J Reibenwein A Alfanz P Horak BC Schmid L Hefler R Horvat A Reinthaller R Zeillinger M Krainer 2007 In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway Br J Cancer 96 485 491 1:CAS:528:DC%2BD2sXhtlKjt70%3D 10.1038/sj.bjc.6603581 17245339 (Pubitemid 46215221)
6. LK Shawver D Slamon A Ullrich 2002 Smart drugs: tyrosine kinase inhibitors in cancer therapy Cancer Cell 1 117 123 1:CAS:528: DC%2BD38XivVegsb4%3D 10.1016/S1535-6108(02)00039-9 12086869
7. K McKeage CM Perry 2002 Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2 Drugs 62 209 243 1:CAS:528:DC%2BD38XhvFKltb0%3D 10.2165/00003495-200262010-00008 11790161
8. MP Goetz DO Toft MM Ames C Erlichman 2003 The Hsp90 chaperone complex as a novel target for cancer therapy Ann Oncol 14 1169 1176 1:STN:280: DC%2BD3szkvVaktA%3D%3D 10.1093/annonc/mdg316 12881371 (Pubitemid 37039035)
9. SD Hartson AD Irwin J Shao BT Scroggins L Volk W Huang RL Matts 2000 p50(cdc37) is a nonexclusive Hsp90 cohort which participates intimately in Hsp90-mediated folding of immature kinase molecules Biochemistry 39 7631 7644 1:CAS:528:DC%2BD3cXjs1Knu74%3D 10.1021/bi000315r 10858314 (Pubitemid 30422083)
10. JC Young I Moarefi FU Hartl 2001 Hsp90: a specialized but essential protein-folding tool J Cell Biol 154 267 273 1:CAS:528:DC%2BD3MXlsVOjs7k%3D 10.1083/jcb.200104079 11470816 (Pubitemid 34286138)
11. J Terry JM Lubieniecka W Kwan S Liu TO Nielsen 2005 Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models Clin Cancer Res 11 5631 5638 1:CAS:528:DC%2BD2MXmvFSmu7k%3D 10.1158/1078-0432.CCR-05-0398 16061882 (Pubitemid 41060842)
12. D Seigneurin-Berny A Verdel S Curtet C Lemercier J Garin S Rousseaux S Khochbin 2001 Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways Mol Cell Biol 21 8035 8044 1:CAS:528:DC%2BD3MXotl2gtLs%3D 10.1128/MCB.21.23.8035-8044. 2001 11689694 (Pubitemid 33051794)
13. C Boyault Y Zhang S Fritah C Caron B Gilquin SH Kwon C Garrido TP Yao C Vourc'h P Matthias S Khochbin 2007 HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates Genes Dev 21 2172 2181 1:CAS:528:DC%2BD2sXhtVaks73M 10.1101/gad.436407 17785525 (Pubitemid 47360839)
14. Y Zhang N Li C Caron G Matthias D Hess S Khochbin P Matthias 2003 HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo Embo J 22 1168 1179 1:CAS:528:DC%2BD3sXit1yls7c%3D 10.1093/emboj/cdg115 12606581 (Pubitemid 36313600)
15. JJ Kovacs PJ Murphy S Gaillard X Zhao JT Wu CV Nicchitta M Yoshida DO Toft WB Pratt TP Yao 2005 HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor Mol Cell 18 601 607 1:CAS:528:DC%2BD2MXltFOksb4%3D 10.1016/j.molcel.2005.04.021 15916966 (Pubitemid 40726236)
16. AS Beutler S Li R Nicol MJ Walsh 2005 Carbamazepine is an inhibitor of histone deacetylases Life Sci 76 3107 3115 1:CAS:528:DC%2BD2MXjs1Ontbs%3D 10.1016/j.lfs.2005.01.003 15850602 (Pubitemid 40585711)
17. G Kuminek JM Kratz R Ribeiro RG Kelmann BV de Araújo HF Teixeira CM Simões LS Koester 2009 Pharmacokinetic study of a carbamazepine nanoemulsion in beagle dogs Int J Pharm 378 146 148 1:CAS:528: DC%2BD1MXovFKqtbc%3D 10.1016/j.ijpharm.2009.05.055 19501150
18. MM Bradford 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 72 248 254 1:CAS:528:DyaE28XksVehtrY%3D 10.1016/0003-2697(76)90527- 3 942051
19. X Yu ZX Guo MG Marcu L Neckers DM Nguyen GA Chen DS Schrump 2002 Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228 J Natl Cancer Inst 94 504 513 1:CAS:528: DC%2BD38Xjt1Ciur8%3D 11929951
20. AR Guardiola TP Yao 2002 Molecular cloning and characterization of a novel histone deacetylase HDAC10 J Biol Chem 277 3350 3356 1:CAS:528: DC%2BD38XhtVaksbg%3D 10.1074/jbc.M109861200 11726666 (Pubitemid 34953202)
21. SH McLaughlin F Sobott ZP Yao W Zhang PR Nielsen JG Grossmann ED Laue CV Robinson SE Jackson 2006 The co-chaperone p23 arrests the Hsp90 ATPase cycle to trap client proteins J Mol Bio 356 746 758 1:CAS:528:DC%2BD28XotVKqtg%3D%3D 10.1016/j.jmb.2005.11.085 (Pubitemid 43139334)
22. WK Kelly PA Marks 2005 Drug insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid Nat Clin Pract Oncol 2 150 157 1:CAS:528:DC%2BD2MXktlWrtbw%3D 10.1038/ncponc0106 16264908 (Pubitemid 40823166)
23. PB Lam LN Burga BP Wu EW Hofstatter KP Lu GM Wulf 2008 Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability Mol Cancer 7 91 10.1186/1476-4598-7-91 19077306
24. W Xu S Soga K Beebe MJ Lee YS Kim J Trepel L Neckers 2007 Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition Br J Cancer 97 741 744 1:CAS:528:DC%2BD2sXhtVWksLzI 10.1038/sj.bjc.6603950 17712310 (Pubitemid 47396295)
25. W Xu L Neckers 2007 Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells Clin Cancer Res 13 1625 1629 1:CAS:528:DC%2BD2sXivV2gsbc%3D 10.1158/1078-0432.CCR-06-2966 17363512 (Pubitemid 46952925)
26. W Fiskus Y Ren A Mohapatra P Bali A Mandawat R Rao B Herger Y Yang P Atadja J Wu K Bhalla 2007 Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90 Clin Cancer Res 13 4882 4890 1:CAS:528: DC%2BD2sXptVGmtL0%3D 10.1158/1078-0432.CCR-06-3093 17699868 (Pubitemid 47294796)
27. P Bali M Pranpat J Bradner M Balasis W Fiskus F Guo K Rocha S Kumaraswamy S Boyapalle P Atadja E Seto K Bhalla 2005 Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors J Biol Chem 280 26729 26734 1:CAS:528:DC%2BD2MXmt1Ggs7w%3D 10.1074/jbc.C500186200 15937340 (Pubitemid 41040705)
28. MV Blagosklonny R Robey DL Sackett L Du F Traganos Z Darzynkiewicz T Fojo SE Bates 2002 Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity Mol Cancer Ther 1 937 941 1:CAS:528:DC%2BD3sXmvFOntg%3D%3D 12481415
29. R Furumai A Matsuyama N Kobashi KH Lee M Nishiyama H Nakajima A Tanaka Y Komatsu N Nishino M Yoshida S Horinouchi 2002 FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases Cancer Res 62 4916 4921 1:CAS:528:DC%2BD38Xmslylu78%3D 12208741
30. S Remy H Beck 2006 Molecular and cellular mechanisms of pharmacoresistance in epilepsy Brain 129 18 35 10.1093/brain/awh682 16317026 (Pubitemid 43063756)